Your search for non small cell lung cancer returned 3 results

Cancer patients with biomarker-positive tumors have better outcomes on immune checkpoint inhibitor therapy, a meta-analysis suggests.

A regulatory decision is expected on November 27, 2023.

Improvement seen compared with chemotherapy alone for first-line treatment of advanced non-small cell lung cancer.